Thrivent Financial for Lutherans Sells 51,825 Shares of Danaher Co. (NYSE:DHR)

Thrivent Financial for Lutherans reduced its position in shares of Danaher Co. (NYSE:DHR) by 8.2% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 582,706 shares of the conglomerate’s stock after selling 51,825 shares during the period. Thrivent Financial for Lutherans owned about 0.08% of Danaher worth $162,003,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in DHR. Benjamin Edwards Inc. boosted its holdings in shares of Danaher by 1.8% in the 2nd quarter. Benjamin Edwards Inc. now owns 2,153 shares of the conglomerate’s stock worth $538,000 after acquiring an additional 38 shares in the last quarter. Wedge Capital Management L L P NC boosted its stake in Danaher by 3.2% in the third quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate’s stock worth $342,000 after purchasing an additional 38 shares in the last quarter. Patrick M Sweeney & Associates Inc. grew its holdings in shares of Danaher by 3.4% during the second quarter. Patrick M Sweeney & Associates Inc. now owns 1,230 shares of the conglomerate’s stock worth $307,000 after purchasing an additional 40 shares during the last quarter. Trust Co of Kansas increased its stake in shares of Danaher by 4.1% in the second quarter. Trust Co of Kansas now owns 1,022 shares of the conglomerate’s stock valued at $255,000 after buying an additional 40 shares in the last quarter. Finally, Abacus Planning Group Inc. raised its holdings in shares of Danaher by 0.7% in the second quarter. Abacus Planning Group Inc. now owns 5,439 shares of the conglomerate’s stock valued at $1,359,000 after buying an additional 40 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Price Performance

Shares of NYSE DHR opened at $230.50 on Friday. Danaher Co. has a fifty-two week low of $206.30 and a fifty-two week high of $281.70. The stock has a market capitalization of $166.49 billion, a price-to-earnings ratio of 43.99, a PEG ratio of 4.24 and a beta of 0.85. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The business has a 50-day moving average of $262.20 and a 200-day moving average of $260.47.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.14. The firm had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The business’s quarterly revenue was up 3.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.02 EPS. As a group, sell-side analysts predict that Danaher Co. will post 7.51 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were given a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.47%. The ex-dividend date was Friday, September 27th. Danaher’s dividend payout ratio (DPR) is presently 20.61%.

Insider Transactions at Danaher

In related news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the transaction, the senior vice president now owns 4,212 shares in the company, valued at approximately $1,130,374.44. This trade represents a 18.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 11.10% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities research analysts have weighed in on the stock. Evercore ISI raised their price objective on shares of Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. StockNews.com upgraded shares of Danaher from a “hold” rating to a “buy” rating in a research report on Wednesday, November 6th. Royal Bank of Canada reduced their price objective on Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. Leerink Partners lifted their target price on Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Finally, UBS Group cut their price target on Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a research note on Wednesday, October 23rd. Five research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $287.16.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.